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Abstract
Introduction A single centre has reported that implementation
of an intensive insulin protocol, aiming for tight glycaemic control
(blood glucose 4.4 to 6.1 mmol/l), resulted in significant
reduction in mortality in longer stay medical and surgical
critically ill patients. Our aim was to determine the degree to
which tight glycaemic control can be maintained using an
intensive insulin therapy protocol with computerized decision
support and to identify factors that may be associated with the
degree of control.
Methods At a general adult 22-bed intensive care unit, we
implemented an intensive insulin therapy protocol in
mechanically ventilated patients, aiming for a target glucose
range of 4.4 to 6.1 mmol/l. The protocol was integrated into the
computerized information management system by way of a
decision support program. The time spent in each predefined
blood glucose band was estimated, assuming a linear trend
between measurements.
Results Fifty consecutive patients were investigated, involving
analysis of 7,209 blood glucose samples, over 9,214 hours. The
target tight glycaemic control band (4.4 to 6.1 mmol/l) was
achieved for a median of 23.1% of the time that patients were
receiving intensive insulin therapy. Nearly half of the time
(median 48.5%), blood glucose was within the band 6.2 to 7.99
mmol/l. Univariate analysis revealed that body mass index (BMI),
Acute Physiology and Chronic Health Evaluation (APACHE) II
score and previous diabetes each explained approximately 10%
of the variability in tight glycaemic control. BMI and APACHE II
score explained most (27%) of the variability in tight glycaemic
control in the multivariate analysis, after adjusting for age and
previous diabetes.
Conclusion Use of the computerized decision supported
intensive insulin therapy protocol did result in achievement of
tight glycaemic control for a substantial percentage of each
patient's stay, although it did deliver 'normoglycaemia' (4.4 to
about 8 mmol/l) for nearly 75% of the time. Tight glycaemic
control was difficult to achieve in critically ill patients using this
protocol. More sophisticated methods such as continuous
blood glucose monitoring with automated insulin and glucose
infusion adjustment may be a more effective way to achieve tight
glycaemic control. Glycaemia in patients with high BMI and
APACHE II scores may be more difficult to control using
intensive insulin therapy protocols. Trial registration number 05/
Q0505/1.
Introduction
In a landmark study [1] of 1,548 patients, the majority of whom
had undergone cardiac surgery, intensive insulin therapy (IIT)
aiming at achieving tight glycaemic control (TGC) reduced
absolute mortality on the intensive care unit from 8% to 4.6%.
Patients receiving IIT were managed to an intended target
APACHE = Acute Physiology and Chronic Health Evaluation; BMI = body mass index; CIT = conventional insulin therapy; ICU = intensive care unit; 
IIT = intensive insulin therapy; TGC = tight glycaemic control.Critical Care    Vol 11 No 4    Shulman et al.
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blood glucose of 4.4 to 6.1 mmol/l, whereas control patients
were managed to a 'conventional' target blood glucose of 10
to 11.1 mmol/L (conventional insulin therapy [CIT]). The study
reported that the benefits of IIT were most pronounced in
patients staying more than 5 days in the intensive care unit
(ICU). A subsequent reanalysis suggested that 3 days or more
were required for benefit to be realized [2]. Furthermore,
bloodstream infections, acute renal failure requiring renal
replacement therapy, red blood cell transfusions and critical ill-
ness polyneuropathy were all reduced in the IIT group. In a
subsequent study of 1,200 patients, the same investigators
reported that IIT also reduced morbidity in patients admitted to
a medical ICU; mortality benefits were only seen in patients
treated with IIT for 3 days or longer [2]. Although the overall
hospital mortality was no different between the two groups
(37% in the IIT group versus 40% in the CIT group), in the
longer stay patients mortality was reduced with IIT (53% in the
CIT group versus 43% in the IIT group). The reason for the
worse outcome with IIT in the shorter stay patients is unclear
but it may have been due to the inappropriate inclusion in the
study of patients in whom treatment was futile.
Controversy surrounds several areas of TGC. First, the precise
blood glucose targets are unclear [3-5]. Data from one obser-
vational study [6] suggested that a less stringent target blood
glucose range of 4 to 8 mmol/l may achieve similar mortality
benefits. Similarly, in a historical single-centre observational
study, Krinsley [7] reported a significant reduction in mortality
in a mixed medical-surgical ICU following the introduction of
an IIT protocol, despite a less stringent blood glucose target
of less than 7.8 mmol/l. In contrast, a post hoc analysis of the
original Leuven study [8] indicated that intermediate glycae-
mic control, with blood glucose between 6.1 and 8.3 mmol/l,
only conferred intermediate advantages when compared with
a target range of 4.4 to 6.1 mmol/l.
Second, complex protocols are required to achieve TGC in
clinical practice, with frequent blood glucose measurements
and changes to insulin infusion rates depending on the rate of
change of blood glucose levels [1,7,9]. A major concern about
stringent glycaemic targets outside the focus of a clinical trial
is that patients may be at increased risk for hypoglycaemia.
Several IIT protocols have resulted in significant increases in
the incidence of severe hypoglycaemia [1,2,10]. Indeed, this
led, at least in part, to the premature cessation of the multi-
center German Efficacy of Volume Substitution and Insulin
Therapy in Severe Sepsis (VISEP) study [10]. Another proto-
col was associated with a doubling in the incidence of mild
hypoglycaemia (2.3 to 2.8 mmol/l), although severe hypogly-
caemic episodes (<2.3 mmol/l) were not more common [7]. A
nurse managed IIT protocol (4.5 to 6.1 mmol/l) was associ-
ated with significantly fewer hypoglycaemic episodes than a
protocol in which insulin dose was adjusted at the attending
clinician's discretion [9].
Finally, the existing literature demonstrates that noncomputer-
ized 'paper-based' TGC protocols may not achieve prolonged
target glycaemia. The degree of glucose control achieved is
not comprehensively described in the Leuven study [1]; the
proportion of the time during which the patients' blood glu-
cose concentrations were in the target range was not
reported, and blood glucose levels at 06:00 hours were 5.7 ±
1.1 mmol/l in the IIT group, suggesting that about 35.6% of
the measurements at this time exceeded 6.1 mmol/l. Results
with another paper-based TGC protocol indicated that 58% of
samples from 128 patients had a blood glucose concentration
in excess of 6.1 mmol/L [11]. Relatively short durations of
achievement of target glycaemia were reported following the
introduction of a nurse implemented IIT protocol [9]; the dura-
tion of time spent within the target glycaemic range was only
11.5 hours/day. In a recent advance, researchers from New
Zealand developed and piloted a model-based approach that
manages TGC on the basis of controlling nutritional intake in
addition to insulin [12,13]. In a pilot study of 19 patients, they
reported that 62% of measurements (taken every 1 to 2 hours)
were in the glycaemic range from 4.1 to 6.1 mmol/l in a general
ICU population.
We hypothesized that implementing an IIT protocol (Additional
file 1) using computerized decision support would reduce the
incidence of hypoglycaemia and increase the proportion of
time spent within the target glycemic range. Therefore, we
implemented a modified IIT protocol [9] into a bedside clinical
information system. The protocol was aimed at achieving a
blood glucose of 4.4 to 6.1 mmol/l. We considered that the
computerized decision support would make a complex IIT pro-
tocol feasible in a busy clinical setting.
The aims of this study were to evaluate the quality of glucose
control achieved by this system and to identify any factors that
may explain variability in glycaemic control.
Materials and methods
Patients
This was an observational study of patients treated using the
IIT protocol on the ICU. Following ethical approval and training
of medical and nursing staff, consecutive patients admitted to
the Middlesex and University College Hospitals ICU who were
treated with the IIT protocol, from 10 January to 25 June 2005,
were studied prospectively. Patients were included if they
were mechanically ventilated, and it was anticipated that this
would continue for at least 24 hours. Additional inclusion cri-
teria included the presence of a central venous line and arterial
cannula. Patients with diabetic ketoacidosis or diabetic nonke-
totic hyperosmolar coma were excluded.
Intensive insulin therapy protocol
The IIT protocol (Additional file 1) was developed by the ICU
consultant (PG), based on a published protocol [9], in con-
junction with the senior ICU team including doctors, nursesAvailable online http://ccforum.com/content/11/4/R75
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and the unit pharmacist (RS). The protocol was introduced
after a comprehensive educational programme into the ration-
ale and logistics of glucose control in the critically ill. The pro-
tocol was facilitated by a computerized decision-support
system that was designed in-house as part of our clinical infor-
mation system (QS; GE Healthcare, Anapolis, MD, USA). The
protocol was initiated 2 months before the study started in
order to allow time to resolve initial difficulties. In this compu-
terized decision support system, the nurse inputs the blood
glucose measurement and the current insulin dose into the
bedside computer. The decision support system uses this
blood glucose value and the previous measurement to derive
a new recommended insulin dose, following the IIT protocol
(Additional file 1). For example, if the insulin was currently run-
ning at 6 units per hour and the latest blood glucose measure-
ment was 4.4 mmol/l, whereas the previous blood glucose
measurement was 6 mmol/l, then the program would recom-
mend reducing the insulin dose to 5 units per hour.
The ICU employs an early enteral feeding strategy, and feed-
ing is usually commenced within 24 hours of admission. Feed-
ing is initiated at 30 ml/hour, and this is doubled if it is
adequately tolerated after 4 hours. If tolerated, after a further 4
hours the feed is optimized to a final rate in relation to the
patient's weight. The IIT protocol dictated that glucose 50%
infusion was administered until full enteral feeding was estab-
lished. The glucose was administered at a constant rate from
accurate volumetric infusion devices.
Intravenous corticosteroids were administered as intermittent
boluses, rather than as a continuous infusion. No attempt was
made to avoid medications diluted in glucose and adminis-
tered intermittently. Continuous intravenous infusions were
routinely diluted in 5% glucose, unless there were specific
incompatibilities.
Data collection
Blood glucose data were obtained from two sources: glucose
meter readings (Glucometer Elite™; Bayer Diagnostics, New-
bury, UK) and the ICU blood gas analyzer (ABL 625; Radiom-
eter, Crawley, UK). The blood gas analyzer underwent daily
control by the unit's medical physicists. After 1 month glucose
meters were also used to guide IIT to facilitate bedside man-
agement. Only blood glucose levels measured from arterial
blood samples (not finger sticks) were used to guide therapy
in the IIT protocol. All baseline, outcome data and concomitant
drugs affecting glycaemia were recorded from the clinical
information system.
Severe hypoglycaemia (blood glucose ≤2.2 mmol/l) and
hyperglycaemic (blood glucose >10 mmol/l for >2 hours)
events were individually analyzed to identify features that were
probably causative.
Analysis of glucose control
The blood glucose findings for each patient were manually
input into the clinical information system by the bedside nurse,
and this was downloaded into a Microsoft Excel spreadsheet.
A macro formula was used to calculate the time spent in seven
predefined glycaemic bands (0 to 2.2, 2.3 to 4.39, 4.4 to 6.1,
6.2 to 7.99, 8 to 9.9, 10 to 11.1, and >11.1 mmol/l). It was
assumed that blood glucose values trended linearly between
successive measurements. An element of protocol adherence
was studied by assessment of whether each blood glucose
assay was conducted within the time stated in the protocol.
Although it would be expected that the assays would follow
the time interval stated in the protocol, it was recognized that
there might be a delay until the nurses recorded the result on
the computer, and hence a 50% tolerance limit was accepted
in the assessment of protocol adherence.
Analysis of the impact of drugs affecting glycaemic control
was undertaken by recording those who were prescribed
these drugs for a part or the whole of their IIT course, and com-
paring glycaemic control between these patients and those
who were not prescribed these agents. Commonly used drugs
known to affect blood glucose levels are listed in Table 1.
Statistical analysis
All data analyses were conducted using SPSS 13.0 for Win-
dows (SPSS Inc., Chicago, IL, USA). Data are presented as
mean ± standard deviation or as median (interquartile range),
as appropriate. Variables thought potentially to be clinically rel-
evant to TGC were identified a priori. Linear regression was
used to help identify factors that were associated with TGC.
Results
Fifty consecutive ICU patients were recruited, and their base-
line characteristics are summarized in Tables 2 and 3 and out-
comes in Table 4.
The median (interquartile range) duration of the IIT course was
4.3 (1.4 to 11.5) days. Eight (16%) patients had an IIT course
of less than 24 hours. Twenty-two patients (44%) had an IIT
course of less than 3 days. A total of 7,209 blood glucose
measurements (including glucose meter and blood gas analy-
sis) were recorded for the 50 patients, over a total time of
9,214 hours. The number of assays taken specifically to guide
IIT was 4,891, equating to one measurement every 113 min.
The median (interquartile range) time taken from the initiation
of the IIT protocol to first achievement of the target range of
4.4 to 6.1 mmol/L was 10.5 (4.8 to 14.5) hours. Graphical
exploration demonstrated that the proportion of time spent in
the target blood glucose range did not change over the 6-
month study period (Figure 1).
The time spent in each glycaemic band was determined and
expressed as a percentage of the total duration of IIT (FigureCritical Care    Vol 11 No 4    Shulman et al.
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2). Patients spent the most time (median 48.5%) with a blood
glucose between 6.2 and 7.99 mmol/l. The TGC target of 4.4
to 6.1 mmol/l was achieved for a median of 23.1% of the ther-
apy. Relatively brief proportions of time were spent in the
hyperglycaemic ranges 10 to 11.1 mmol/l and above 11.11
mmol/l (median 2.0% and 1.4%, respectively). The degrees of
glycaemic control for various patient groups are presented in
Table 5.
Hypoglycaemic events were defined as episodes during which
the blood glucose was 2.2 mmol/l or less. This occurred on 14
occasions, affecting five patients (10%). These included one
medical and four surgical patients. No clinical sequelae were
noted from these episodes. Cumulatively, little time (median
0.04%) was spent in the severely hypoglycaemic range of 0 to
2.2 mmol/l or in the hypoglycaemic range 2.3 to 4.39 mmol/l
(median of 1.7%). Some common themes emerged. First, the
events did not appear to be associated with the effects of
additional medication, although one of the patients did receive
Table 1
Commonly used medications that can produce hypoglycaemia and hyperglycaemia as adverse effects
Adverse effect Drugs
Hypoglycaemia Angiotensin-converting enzyme inhibitors
Budesonide
Chlorpromazine
Disopyramide (isolated cases)
Ethanol
Quinine
Hyperglycaemia Adrenaline (ephinephrine)
β2 agonists (in diabetes)
Ciclosporin
Clonidine
Corticosteroids
Diazoxide
Diuretics (mainly thiazides)
Glucose
Isoniazid
Nicotinic acid
Noradrenaline (norephinephrine)
Octreotide
Olanzapine
Oral contraceptives
Phenytoin
Risperidone
Rituximab
Theophylline
Miscellaneous Acetazolamide (potentiates action of hypoglycaemics)
Amitriptyline (elevates or decreases blood sugar levels)
Imipramine (isolated cases of increase or decrease in blood sugar levels)
Pentamidine (life threatening hypoglycaemia, less severe hyperglycaemia)
Tacrolimus (elevates or decreases blood sugar levels)
Triamterene (impaired glucose metabolism [<1/100] [33])Available online http://ccforum.com/content/11/4/R75
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a corticosteroid at the time of the event. In several cases the
protocol was not followed. It was common for blood glucose
samples not to have been taken frequently enough. Interrup-
tion in enteral feed was another common cause of
hypoglycaemia. In three instances the records on the informa-
tion system gave conflicting and ambiguous information, mak-
ing interpretation impossible and suggesting inadequate
documentation.
There were 28 hyperglycaemic episodes (defined as blood
glucose >10 mmol/l for at least 2 hours). Fifteen (30.0%)
patients treated with the IIT protocol experienced at least one
hyperglycaemic episode. Of the 28 episodes, 19 (68%)
occurred within the first 36 hours of therapy and appeared to
correspond to nasogastric feeding plus glucose
supplementation.
Box-plots (not shown) comparing glycaemic profiles of
patients administered medicines causing hyperglycaemia (n =
32) with the profiles of those who were not receiving such
medications (n = 18) did not show any clear difference. This
may reflect the relatively small number of cases, however.
It was found that a median 47.0% (32.9% to 59.0%) of assays
were not taken within the time frame stated in the IIT protocol.
However, in the univariate analysis, the proportion of correctly
timed assays did not account for the variability in the percent-
age of time spent within the target TGC range (Table 6).
In this study, the percentage time spent in the target range
(blood glucose 4.4 to 6.1 mmol/l) was taken to describe TGC,
and the distribution was found to satisfy the conditions of a
normal distribution. Seven factors were chosen that might clin-
ically be expected to influence TGC (Table 6). Univariate anal-
ysis (Table 6) suggested that body mass index (BMI)
accounted for 13% of the variability, with a higher BMI associ-
ated with a lower TGC. Acute Physiology and Chronic Health
Evaluation (APACHE) II score accounted for 11% of the vari-
ability, again with a higher score associated with poorer gly-
caemic control. TGC was worse in patients with diabetes
mellitus (10% of the variability explained). There was a sug-
gestion that females had better TGC than males, by an aver-
age of 7.1%. Age did not appear to explain variability in TGC.
In the multivariate analysis (Table 7), BMI, sex, previous diabe-
tes and APACHE II score accounted for 27% of the variability
in percentage time spent in the target TGC range.
Discussion
The key finding was that attempting to achieve TGC, using a
complex protocol assisted by computerized decision support,
was extremely difficult. Our experience highlights the
difficulties of applying the results of highly controlled clinical
Table 2
Baseline characteristics of patients
Characteristic Value
Male (n [%]) 34 (68%)
Age (years; median [IQR]) 66 (54 to 73)
BMI (median [IQR])a 25.5 (22.3 to 29.1)
Underweight (BMI <18.5 kg/m2; n [%]) 4 (8%)
Overweight but not obese (BMI 25 to 30 kg/m2; n [%]) 19 (38%)
Obese (BMI >30 kg/m2; n [%]) 6 (12%)
Patients taking drugs influencing glycaemia (n [%])b 36 (72%)
Parenteral nutrition for all or part of admission (n [%]) 9 (18%)
Enteral nutrition for all or part of admission (n [%]) 43 (86%)
Glucose 50% infusion for all or part of admission (n [%]) 42 (84%)
APACHE II score (first 24 hours; median [IQR])c 23 (17–29)
SAPS II score (first 24 hours; median [IQR])d 47 (35–64)
History of diabetes (n [%]) 6 (12%)
Treated with insulin (n [%]) 1 (2%)
Treated with oral agents (n [%]) 4 (8%)
Diet controlled (n [%]) 2 (4%)
Fifty patients were included in the study. aBody mass index (BMI) calculated as weight (kg) divided by height (metres) squared. bSee Table 1 for a 
list of commonly used drugs known to affect glycaemia. cAcute Physiology and Chronic Health Evaluation (APACHE) II score range 0 to 71. 
dSimplified Acute Physiology Score (SAPS)II range 31 to 163. IQR, interquartile range.Critical Care    Vol 11 No 4    Shulman et al.
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trials to everyday practice [14]. The target blood glucose
range of 4.4 to 6.1 mmol/l was only achieved for a median of
23% of the time that the protocol was used, although the next
band – 6.2 to 7.99 mmol/l – was achieved for 49% of the time.
The time to first reach the target blood glucose range of 10.5
hours was comparable to that reported by Kanji and co-work-
ers [9] with a similar target.
This main finding has not been a feature of other published
work. It contrasts starkly with the findings reported by Kanji
and coworkers [9], in which the similar target range of 4.5 to
6.1 mmol/l was achieved for 47% of the time in the protocol
group. It is also discordant with the report from the Specialized
Relative Insulin and Nutrition Tables (SPRINT) investigators
[12], who found that over 60% of the results were in the 4.1
to 6.1 mmol/l. Dutch investigators developed and evaluated
the Glucose Regulation for Intensive care Patients (GRIP)
computerized decision support system in a short-stay cardiac
ICU, aiming for a target blood glucose of 4 to 7.5 mmol/L [15].
This target was achieved for 78% of the time, following a
median of 4.9 daily blood glucose assays. The Glucommander
insulin dosing software has been in use for many years, and
good glycaemic control has been reported in mixed patient
groups; however, evidence in critically ill patients has not been
reported separately [16]. In both Leuven studies [1,2] there
was insufficient detail in the results to allow adequate assess-
ment of the degree of control achieved in terms of the propor-
tion of course in various glycaemic ranges. Other studies
reporting on similar aspects of control did not employ the key
aspects of the Leuven study, namely a blood glucose target of
4.4 to 6.1 mmol/l and the initial glucose load [15,17-22].
There is a clear need to standardise the protocols for IIT, in
order to address differences in glycaemic targets, nutritional
and glucose supplementation, and insulin dosing strategy.
Our experience suggests that many of the hyperglycaemic
events occurred during the first 36 hours of IIT, which coin-
cides with the establishment of enteral feed while intravenous
glucose is concomitantly administered. This glucose infusion
was solely part of the IIT protocol and was not administered to
other ICU patients prescribed insulin. The clinical value of this
initial glucose infusion is not known and would depend on
whether IIT works by reducing hyperglycaemia or through
Table 3
Reason for intensive care
Reason for intensive care All patientsa Surgicala Medicala
Cardiac 5 (10%) 4 (21.1%) 1 (3.2%)
Abdominal 6 (12%) 5 (26.3%) 1 (3.2%)
Trauma 2 (4%) 0 (0%) 2 (6.5%)
Sepsis 3 (6%) 1 (5.3%) 2 (6.5%)
Respiratory failure 23 (46%) 7 (36.8%) 16 (51.6%)
Liver failure 4 (8%) 1 (5.3%) 3 (9.7%)
Pancreatitis 1 (2%) 0 (0%) 1 (3.2%)
History of malignancy 16 (32%) 5 (26.3%) 11 (35.5%)
Total 50 (100%) 19 (38.0%) 31 (62.0%)
Fifty patients were included in the study. Values are expressed as number (%). aPatients could have more than one reason for intensive care.
Table 4
Patient outcomes
Outcome Value
ICU LOS (days; median [IQR]) 7.0 (3.0 to 21.3)
28-day survival (n [%]) 34 (64.2%)
Mechanical ventilation (days; median [IQR]) 5.5 (2.0 to 15.3)
Patients haemofiltered (n [%]) 13 (26.0%)
Days on haemofiltration (median [IQR])a 4.0 (1.5 to 7.5)
Fifty patients were included in the study. aFor those patients 
undergoing haemofiltration. ICU, intensive care unit; IQR, 
interquartile range; LOS, length of stay.
Figure 1
Percentage of time spent in target glycaemic range for each patient, in  order of inclusion in study Percentage of time spent in target glycaemic range for each patient, in 
order of inclusion in study.Available online http://ccforum.com/content/11/4/R75
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another action of insulin, which may be anti-inflammatory, anti-
coagulant, or anabolic [23]. Our protocol has now been
amended to remove the glucose supplementation as we
employ early enteral feeding. This change has also obviated
the need for a central line, which was required for the glucose
50% infusion. Removal of glucose supplementation is in keep-
ing with practice in some other units [24]. An alternative would
have been to adopt a dynamic glucose algorithm that includes
the total glucose (including any feed) as an input. A dynamic
algorithm uses data from a previous blood glucose response
to a change in insulin, and thus it 'learns' how an individual
patient responds to insulin and feed, and advises accordingly.
Other protocol changes include employing IIT only in those
patients who the admitting doctor expects to be on the ICU for
at least 3 days. Furthermore, we have now employed a simpli-
fied frequency of blood glucose measurement (to address the
low frequency of blood glucose assay rate found in this study)
and an educational program to enforce the importance of
adherence. The impact of these changes will be analyzed in
due course.
There are differences in the IIT protocols in use [24]. Research
is required to identify the most effective protocol and the best
way to organize the ICU management of IIT [24,25]. The inci-
dence of severe hypoglycaemia was too low and our study
was insufficiently powered to assess reliably any association
with survival. Because this was a study of existing practice, no
a priori acceptable levels of efficacy or safety were set.
The method used here to estimate the time during which the
blood glucose concentration was within the predefined gly-
caemic bands [6] was superior to those used in other studies,
in which results were pooled and the mean reported
[17,18,21,22]. In another study with a target blood glucose of
4.1 to 6.1 mmol/l [12], the findings were presented as the pro-
portion of results within this range and a wider range. In
another study of true TGC (aiming for a blood glucose con-
centration of 4.4 to 6.1 mmol/l) [9], an assumption was made
that the time between two measurements reflected the time
spent at the later measurement; for instance, if a blood glu-
cose reading was 5 mmol/l, then the time recorded within the
target range was the interval between this and the immediately
preceding measurement. This assumption is difficult to justify.
The method used to describe glycaemic control in our study is
recommended if blood glucose is not measured at a uniform
frequency.
The factors identified that may explain variability in TGC were
BMI, APACHE II score, previous diabetes and sex. As a prac-
tical consequence, patients with high BMI or APACHE II
scores may require more frequent blood glucose measure-
ment if IIT is employed. Because APACHE II score is a severity
of illness scale that correlates well with mortality [26], it may
be that a high score reflects critical illness and associated
insulin resistance. Finney and co-workers [6] identified an
association between increasing insulin dose and increased
mortality; this was also reported by Van den Berghe and co-
workers [8].
The finding that 16% of patients had an IIT course of under 24
hours suggests that they were not expected to have the mor-
tality gains from IIT reported in the major studies [1,2]. The
appropriate reasons for these short courses were futility of
care (two cases) and conversion from IIT to a glucose-insulin-
potassium regimen (one case). The inappropriate reason for a
short IIT course was on extubation with a short course of
mechanical ventilation (five cases). This highlights the difficulty
in predicting which patients will have longer stays in the ICU
[2]. However, the blood glucose data from these patients were
included in the results because we aimed to describe imple-
mentation of IIT in 'real life'.
The finding that 47% of blood glucose assays were not within
the time frame stated in the protocol may reflect burden of
additional work for the nurse that is associated with IIT. Inter-
estingly, however, there did not appear to be a relationship
Table 5
Glycaemic control of various patient groups
Patient group Blood glucose
4.4 to 6.1 mmol/l 6.2 to 7.99 mmol/l
All patients (n = 50) 23.1% (15.4 to 29.8) 48.5% (36.9 to 60.8)
Surgical patients (n = 19) 23.9% (14.4 to 31.0) 55.7% (40.6 to 63.9)
Medical patients (n = 31) 22.1% (16.7 to 29.8) 40.3% (30.0 to 56.6)
History of diabetes (n = 6) 11.6% (2.9 to 20.8) 36.3% (15.3 to 43.5)
No history of diabetes (n = 44) 23.9% (18.4 to 30.7) 51.6% (38.8 to 63.0)
Co-prescription of drug(s) causing hyperglycaemia (n = 32) 26.3% (19.0 to 30.7) 47.7% (37.8 to 59.7)
Co-prescription of drug(s) causing hypoglycaemia (n = 5) 7.0% (2.0 to 31.6) 62.8% (17.4 to 75.4)
Shown are the percentages of the intensive insulin therapy course spent in the specified glycaemic ranges. Values are expressed as median 
(interquartile range).Critical Care    Vol 11 No 4    Shulman et al.
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between correct timing of blood glucose assays and TGC,
based on the univariate analysis. As in most areas of therapy,
collaboration of the nurses is crucial to successful application
of IIT. The significant impact of IIT on nursing workload is such
that nurses should be involved in all aspects of protocol
design, training, implementation and revaluation. Our protocol
has subsequently been amended, in the light of these findings
and in discussion with the nurses, to reduce the frequency of
blood glucose monitoring to a more reasonable frequency
(usually 2 hourly, rather than hourly).
Computerized clinical decision support has been defined as
information systems designed to improve decision making,
including patient-specific advice, which is reviewed by a health
care practitioner before clinical action [27]. Our system met
these criteria. One view is that it is not the paper or computer
that makes the difference in how well TGC is achieved; rather,
it is the protocol used. TGC was suitable for computerization
because the IIT protocol was complex and would have been
time consuming for nursing staff to use had it not been for the
computerized decision support.
The main limitation of the study was that blood glucose analy-
sis included measurements based on two different instru-
ments: blood gas analyzer and glucose meter. However, when
the analysis was repeated only using the blood glucose results
used by the nurses (predominantly glucose meter) for the deci-
sion support, similar results were observed; indeed, this would
have been more of an issue had we employed capillary blood
(fingerstick) measurement [28], which we did not. It is
acknowledged that the quality control of bedside glucose
meters was not conducted regularly in a uniform manner. We
were unable to record the amount of insulin administered.
Finally, we did not formally investigate the staff perception of
the IIT protocol.
Conclusion
The introduction of a computerized decision supported IIT pro-
tocol did not produce high quality glycaemic control. Hyperg-
lycaemia was particularly prevalent during the early stages of
IIT, when enteral feed was being established while exogenous
glucose was being administered. Whether exogenous glu-
cose is required at the onset of IIT merits further investigation.
Futhermore, poorer glycaemic control occurred in those
patients with a higher BMI and APACHE II score. More flexible
protocols may be required for these patients. Indeed, intelli-
gent closed loop systems that adjust insulin based on previous
responses are being developed [29,30]. Coupled with contin-
uous intravenous glucose sensors [31,32], these may be able
to provide near perfect control.
Additional files 
Additional file 1 is a pdf file summarizing the ICU intensive
insulin therapy protocol, 2004 to 2006.  
Figure 2
Box and whisker plot of percentage time in predefined glycaemic  ranges Box and whisker plot of percentage time in predefined glycaemic 
ranges. TGC, tight glycaemic control.
Table 6
Univariate analysis of factors affecting the percentage time in 
the target glycaemic range
Parameter P R2
BMI 0.01 13.1%
APACHE II score 0.02 10.8%
History of diabetes mellitus 0.02 10.2%
Gender 0.06 7.1%
Drugs affecting glycaemia 0.27 2.5%
Percentage of correctly timed assays 0.63 0.5%
Age 0.75 0.2%
APACHE, Acute Physiology and Chronic Health Evaluation; BMI, 
body mass index.
Table 7
Multivariate analysis of factors affecting the percentage time in 
the target glycaemic range
Parameter P R2
BMI 0.04
APACHE II score 0.04
Sex 0.19
Previous diabetes 0.50
27%
APACHE, Acute Physiology and Chronic Health Evaluation; BMI, 
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